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ABSTRACT 
The existence of pathogenic viruses was inferred by experiments at the turn of the twentieth 
century. Key developments in detection of viruses, including electron microscopy and monolayer cell 
culture, were made in the middle of that century. However, in terms of patient care, the results from 
the virology laboratory often arrived the patient was ‘better or dead’. The advent of molecular 
techniques, particularly polymerase chain reaction and more recently whole genome sequencing 
made timely and accurate diagnosis of viral infections feasible. A range of approaches have been 
taken to identify and characterise new viruses. Vaccines against viruses have made it possible to 
eliminate two pathogenic mammalian viruses altogether, with several others close to eradication. 
The role of biomedical scientists working in diagnostic virology is more relevant to patient care than 
ever. 
Introduction 
Advances in the resolution of light microscopes in the seventeenth century, and the observations 
made by pioneers such as Hooke and van Leeuwenhoek, led to the realisation that there are 
organisms which cannot be seen by the naked human eye (‘little animalcules’).[1] In the 1860s, once 
Pasteur had demonstrated that these microscopic organisms did not generate spontaneously, he 
was able to propose the ‘germ theory’ of disease.[2] Building on this, during the late nineteenth 
century, bacteria and parasites isolated from plant, animal and human samples, were observed 
microscopically, described and classified. Once it was possible to culture these micro-organisms in 
vitro, then the method (‘postulates’) for proving the link between a particular organism and a 
clinically described infectious disease was developed by Koch.[2] Thus, the role of clinical and 
diagnostic microbiology in making a useful contribution to patient care and public health was 
established. 
However, it was observed that there were some pathogenic organisms which could pass through 
conventional filters (‘filterable viruses’), but could not be detected by light microscopy and were 
therefore clearly smaller than bacterial cells.[2] Ivanovsky is credited with discovering and 
documenting the first of these – Tobacco Mosaic  Virus – in 1892. The earliest noted connection 
made between a human disease and one of these ‘viruses’ which evaded filtration was for yellow 
fever in 1900.[3] 
However, the real significance of viruses as pathogens was not recognised before the advent of the 
electron microscope and cell culture techniques to grow them in the laboratory in the 1950s. A book 
about ‘microbes’ written for the lay reader in the early 1940s [4] included the following: 
In a highly civilised country, situated in a temper-ate zone, such as England, the Bacteria are 
probably more important incitants of human disease than the Ultramicroscopic Viruses, although 
these are responsible for many serious infections of man. 
The latter half of the twentieth century saw virologists’ workloads expand sufficiently for it to 
become a separate pathology discipline, and it is now recognised that viral infections are responsible 
for significant mortality and morbidity worldwide. Viruses are associated with not only acute, mild 
self-limiting diseases such as the common cold (Rhinoviruses), but with chronic debilitating 
infections (including Hepatitis B Virus and Hepatitis C Virus), epidemic and pandemic infections 
(Influenza A) and new and emerging infections (Human Immunodeficiency Virus, Ebola Virus, Zika 
Virus). Damage caused by viral replication processes and the host’s immune response to the 
infection can also lead to long-term sequelae. It has been estimated that in about 16% of people 
diagnosed with cancer worldwide, the malignancy is attributable to an infection, which may have 
been acquired many years previously.[5] Analysis of global data from 2008 suggested that of the 
12.7 million newly diagnosed cancers, about 610,000 were attributable to infection with Human 
Papillomavirus and 60,000 to Hepatitis B and/or C. These were the second and third most common 
infectious causes, behind Helicobacter pylori, which was recorded in 660,000 cases.[5] Table 1 
provides epidemiological data about selected viral infections for the United Kingdom. This illustrates 
the nature of the work and the workload of diagnostic virology laboratories. The incidence data 
given in Table 1 are the approximate number of new, laboratory confirmed cases recorded each 
year. The number of samples tested will be several times that number, but the demand for testing 
may vary slightly depending on the epidemiology of the virus. Respiratory syncytial virus (RSV) is an 
important cause of severe infection in young children (most commonly bronchiolitis) and the elderly 
(pneumonia; flu-like illness). It is a seasonal infection, with a peak in December/January and 
incidence also varies between years. This means that the demand for RSV investigations on 
respiratory samples is always highest at the start of the year, but the numbers of tests which will be 
performed each year is not necessarily predictable. The annual incidence of measles in the UK also 
varies (Table 1) and recent outbreaks have tended to be focussed in particular geographic areas. 
During the first half of 2012, there was an outbreak centred around Merseyside, during which 1339 
people were identified as possibly having the infection.[6] Laboratory investigations were conducted 
on samples from 881 of them. Evidence supporting the diagnosis of acute measles (anti-measles 
IgM) was found in 359 patients’ saliva, throat swab or urine, which was 39% of probable or possible 
cases.[6] Hepatitis B Virus (HBV) is a major cause of morbidity and mortality globally. At least 240 
million people are thought to be chronic carriers of the virus and over 600,000 deaths are 
attributable to the consequences HBV infection (fulminant hepatitis, liver cirrhosis, hepatic cancer) 
each year.[7] Routine screening for Hepatitis B Virus (HBV) infection is carried out on people from a 
range of demographic groups. These include intravenous drug users (who would be at a relatively 
high risk of infection) and pregnant women (very few of whom would be expected to be carrying the 
virus unwittingly). Nevertheless, since the overall prevalence of HBV in the UK is <0.1 per 100,000 of 
population,[7] finding a blood sample in which the HBV surface anti-gen is detected is not usually a 
daily occurrence for a diagnostic virologist. However, a positive test does create considerable 
amount of work, in terms of testing for HBV markers at the time of first diagnosis and following up 
that patient regularly to monitor the course of their hepatitis. Anti-viral therapy is also available for 
some persistent or recurring infections. In such cases, the efficacy of the treatment would be 
assessed through monitoring of the ‘viral load’. Although many countries have a pol-icy of universal 
vaccination against HBV, in the UK the programme is targeted to those at particular risk. This 
includes health care workers, including pathology laboratory staff. Post vaccination, recipients’ blood 
is tested in the virology laboratory to ensure that their levels of anti-HBV antibody have achieved 
and maintained the recommended protective level of 100 mIU/mL.[8–11] While the estimated 
prevalence of Hepatitis C Virus (HCV) in the UK is around 214,000, (Table 1) this figure is a projection 
which includes people who are asymptomatic and undiagnosed.[12] About 86,000 people are being 
treated for chronic infection with HCV.[12] These patients should all be receiving regular tests for 
the presence and level of HCV RNA in peripheral blood (‘viral load’), to ascertain whether the 
treatment is achieving and maintaining a sustained viral response (SVR). Virology laboratory 
professionals have also risen to the challenges presented by viruses being discovered or changing 
their epidemiology. This includes development of diagnostic tests and development of protocols for 
handling of samples for patients potentially infected with unfamiliar viruses. In the 1980s Human 
Immunodeficiency Virus (HIV) went from an unrecognised virus, to the cause of a feared and fatal 
infection, to the current situation where diagnosis should lead to effective anti-retroviral therapy, 
resulting in a reasonably long and healthy life. The focus of the laboratory work related to HIV has 
also changed. At the start of the epidemic, blood samples for testing were regularly received from 
the ‘worried well’ due to the media publicity around HIV/AIDS. In the twenty-first century, there is 
more emphasis on identifying people with the infection and then monitoring them during 
treatment.[13] The ongoing outbreak of Ebola Virus (EV) in West Africa which began in 2014 [14] 
posed a different set of problems for UK virology laboratory scientists. The public health emergency 
situation continued until March 2016, by which time over 28,000 people had been diagnosed with 
Ebola in Sierra Leone, Guinea and Liberia and over 11,000 had died.[14] Test requests received from 
patients whose travel history suggests that they might have Ebola requires safe handling of the 
samples and sending them to the reference laboratory for testing. The number of confirmed cases 
among people in the UK is very small, however the knowledge and expertise gained through working 
with other blood borne viruses meant that UK virologists were well placed to design test kits and 
then work with colleagues in the areas affected by EV to set up field laboratories.[15] These 
examples illustrate how virology as a pathology discipline has been at the fore-front of laboratory 
technology, exploiting and driving innovation to aid the diagnosis, discovery and elimination of 
viruses. 
Role of laboratory virology in health care 
This article will use some examples to explore these three roles which virology plays within health 
care. Information was gathered by conducting a literature search using Google Scholar as a search 
engine. The keywords used were: diagnosis, discovery, elimination and names of the specifically 
selected laboratory techniques and virus examples. Articles were assessed for their relevance to the 
topics under consideration in each paragraph and any which were not freely available were 
excluded. 
Diagnosis 
By the 1980s, it was possible to culture many viruses of human importance in the laboratory using 
chick egg or monolayer mammalian cell culture. Isolates could be identified to species level on the 
basis of their characteristic cytopathic effect (CPE) – or haemadsorption followed by transmission 
electron microscopy (EM) where no CPE was observable. Further discrimination was possible by 
detecting viral glycoproteins, using antibodies in techniques such as immune electron microscopy, 
immunofluorescence, and haemagglutination inhibition. The problem was that the effects on the 
cells usually took several weeks to become detectable. For example, although Herpes Simplex Virus 
produces CPE within 24–48 h,[16] for its close relative Varicella Zoster Virus, the very distinctive CPE 
takes about 21 days to develop.[17] A more rapid result could be obtained through direct detection 
of viruses, for example EM of vesicular lesions. Unfortunately, HSV and VZV particles appear the 
same (Figure 1), so further investigations would be needed to definitely distinguish between the two 
species.[16, 17] This technique was also routinely used to examine faecal samples, since a wide 
range of viruses could be identified by their EM appearance, including Norovirus (Figure 2). 
However, the limit of detection is 106 particles per gram, the instruments are expensive to buy and 
maintain and – as with other microscopic techniques – only one sample can be examined at a 
time.[18] Methods using fluorescent-labelled antibodies, raised against viral proteins expressed in 
infected host cells, are also available for a relatively quick result.[16, 17] This is also used in diagnosis 
of viruses such as RSV in respiratory specimens (Figure 3). While it is extremely useful in some 
situations, problems with immunofluorescence include lack of adequate cellular material in the 
sample, limited range of available labelled antibodies and the requirement for a fluorescence 
microscope. The other option for diagnosis was detection of specific serum antibody generated in 
response to the viral infection. The main-stay of this was the complement fixation test, which had 
the advantage of being applicable to many infectious agents, but the disadvantage of relying on 
measuring a change in antibody titre between the acute phase of the infection and the convalescent 
stage 14 days later, due to low sensitivity. 
The introduction of molecular genetics techniques such as in situ hybridisation into diagnostic 
pathology allowed for more rapid and sensitive testing for some pathogens, for example the 
detection of Parvovirus in hydrops fetalis [19] and Human Papillomavirus in cervical smears.[20] 
However, the invention of the polymerase chain reaction (PCR) [21, 22] eventually led to a complete 
change in diagnostic virology since it is more sensitive and specific than culture and/or microscopy 
[23, 24] and can provide the result more quickly.[25] As more lab-oratories use PCR, the cost of 
reagents has fallen and automated systems have been created making it possible to process large 
batches of samples, testing for a range viral pathogens. There has also been an added benefit to 
animal welfare, since several widely used cell lines were derived from primary monkey kidneys. The 
loss of the ‘catch all’ advantage of the older techniques can be offset using multiplex PCR [26] such 
as those available for respiratory viruses.[27, 28] It can be used to detect DNA viruses, such as 
adenovirus and rotavirus in children with gastroenteritis symptoms [29] or RNA viruses – via reverse 
transcriptase PCR – including enteroviruses in children with aseptic meningitis.[30] Quantitative 
methods such as TaqMan [31] and Real Time [32] were designed, thus allowing measurement of 
viral load. This can be important in monitoring response to anti-viral treatment in, for example, 
acute influenza,[32] chronic Hepatitis C [33] or post-transplant Cytomegalovirus [34] infections. 
Sequencing of the PCR products is also invaluable, for example for monitoring prevailing influenza 
and RSV strains,[35] Norovirus strain divergences during an outbreak [36] or detecting low copy 
number (‘occult’) or mutant HBV variants which might not be picked up by other diagnostic 
tests.[37] 
The advent of radio – and enzyme- immunoassays (RIA and EIA), particularly using monoclonal 
antibodies changed viral serology. It became feasible to detect IgG and IgM separately instead of 
‘total’ antibody, which allowed earlier detection of acute infection and also confirmation of whether 
the patient had protective antibodies. For example, it is therefore possible to determine whether a 
child presenting with a red rash has measles (detectable levels of IgM against that virus) or pre-
existing IgG antibodies (probably attributable to the MMR vaccine), which would exclude Measles 
Virus as the causative agent.[38] Serological tests could then be adapted to capture serum antigens, 
such as Hepatitis B surface antigen.[39] By the late 1990s, the ‘fourth generation’ tests for the 
presence of HIV were designed to detect a combination of anti-gp41 and anti-p24 antibodies and 
p24 antigen [40] in blood samples. This effectively reduced the ‘window’ between infection and 
diagnosis from the original 3–6 months quoted to patients in the 1980s, to around four weeks.[40] 
This antigen detection format has been adapted to other sample types, for example testing for 
Norovirus in faeces.[41] The EIA principle has been applied to immunchromatographic point of care 
(POCT) kits such as the ones for rapid testing of stool samples for Norovirus (Figure 4). They can be 
set up to detect more than one analyte. For example, there are POCT assays which can detect both 
IgM and IgG against Dengue virus [42] although for the timeliest diagnosis, it is recommended that 
such a kit should be used in conjunction with one which can detect the viral NS1 antigen.[42] 
Similarly, there are POCT kits set up to detect Influenza A (including pandemic strains) and Influenza 
B in one test strip.[43] However, in general, the POCT kits are expensive compared to laboratory 
based assays and the antigen detection formats in particular often have less than ideal sensitivities, 
which means a definitive diagnosis often requires the support of the main virology laboratory. 
Molecular genetics methods and automation have also made screening programmes viable – for 
example the National Chlamydia Screening Programme.[44] Virologists are currently exploring the 
applications for the latest techniques of whole genome and next generation (or ‘deep’) sequencing 
(NGS) within their discipline, as analytical systems become commercially available. [45, 46] For 
example NGS is being applied to sequencing of HIV and HCV isolates to understand evolution of the 
virus within and between patients and monitor the development of resistance to anti-viral drugs.[47, 
48] Similarly, it has been used in epidemiological investigations of Influenza A virus.[46] It has the 
potential to determine which particular strains of HIV express the glycoprotein structures which 
permit (or inhibit) binding to specific host cell receptors (‘co-receptor tropism’); this could help to 
inform decisions about which anti-retrovirals to use in a particular patient.[46, 47] There are some 
technical and scientific issues, especially with sensitivity. Clinical samples contain human tissue, 
which means that both viral and human genomic material are sequenced and this inevitably 
generates a lot of data.[45] Also where there are several strains of one virus, the one present at the 
lowest copy number may not be readily detected.[48] 
The service which diagnostic virology laboratories can offer has therefore been transformed from 
providing confirmation that the patient had a viral infection –  sometime after they have died or 
recovered – to detection of viruses before the person develops symptoms. 
Discovery 
During the twentieth century, virologists were able to utilise the most up to date laboratory 
methods and equipment to discover new viruses. For example, Hepatitis B Virus was found 
somewhat serendipitously by Blumberg in the late 1960s.[49] He was using agar gel diffusion to 
investigate genetic polymorphisms in patients’ serum, as part of an investigation into possible 
inherited susceptibility to disease. Instead, he discovered a reaction between what later transpired 
to be samples from a chronic Hepatitis B virus carrier and someone who had recovered from the 
infection – and therefore had specific antibodies.[49] The virus was subsequently visualised by Dane 
and colleagues, using what was then the very mod-ern, powerful and specialist tool of EM to 
examine serum.[50] The Parvovirus B19 was discovered by Cossart and colleagues a few years later. 
They were following up the Hepatitis B work and also investigating patients’ sera by EM,[51] but 
unexpectedly found an unrelated virus. In contrast, the HIV was isolated from human blood samples 
through the diligence and well-designed experiments of Montagnier and Barré-Sinousi and their 
team [52] who were working to find the causative agent of Acquired Immune Deficiency Syndrome 
(AIDS). They used a combination of suspension cell culture and advanced molecular viral genetics to 
find the virus in human white blood cells and characterise it. Interestingly, the widespread use of 
routine viral culture led to the recognition of a group of viruses, usually found in faecal samples from 
children, which could not be linked to a definitive clinical syndrome. The so-called Enteric Cytopathic 
Human Orphan (ECHO) viruses are now known to be a com-mon cause of acute, mild, self-limiting 
febrile illnesses, although they are occasionally associated with more serious conditions such as viral 
meningitis, myocarditis and conjunctivitis.[53] The opposite occurred in the identification of 
Hepatitis C virus as the cause of most ‘non-A, non-B’ hepatitis. Although a viral cause had long been 
suspected, it had not been found. The presence of immunogenic viral proteins was determined 
through animal experiments (and application of Koch’s postulates). Recombinant peptides were 
prepared from these sequences from which c-DNA clones were made.[54]  This allowed the 
development of a serological test for antibodies against these viral proteins,[55] before the whole 
virus had been isolated, visualised and fully characterised [56] and classified as Hepatitis C. Research 
and diagnostic virologists continue to be challenged to respond to new viruses, including Middle East 
Respiratory Syndrome Coronavirus ‘MERS-CoV’ [57, 58] and emerging viruses, exemplified by the 
outbreak of Ebola in 2014–2015.[15, 59] Molecular genetic techniques such as next generation 
sequencing are powerful and robust enough to contribute to virus discovery.[45] 
Elimination 
Two pathogenic infectious agents have been deliberately eradicated from the world and both are 
viruses, namely Smallpox Virus in 1980 [60] and Rinderpest Virus in 2011 [61] Advances in cell 
culture techniques, safety of medicines and understanding of micro-organism biology during the 
twentieth century made it possible for vaccines to be developed, tested and implemented into mass 
control campaigns. Many of these vaccines are against viruses. Optimistic from the success of the 
Smallpox work, in 1988 the World Health Organisation (WHO) set a target for eradication of polio 
(for which there are two types of vaccine available) by 2000. Vaccination programmes have led to 
interruption of transmission of the virus in most countries and the number of cases has reduced by 
99% from around 350,000 each year in the late 1980s to less than 100 by the mid 2010s.[62] It is still 
endemic in three countries, namely Afghanistan, Nigeria and Pakistan, with outbreaks occurring 
sporadically in several others.[62] However, its elimination remains a realistic possibility. Thanks to 
the surveillance and sequencing work undertaken by laboratory virologists, the distinction between 
wild-type and vaccine-derived polio can be made and it is known that Poliovirus type 2 is no longer 
circulating – and it has therefore been removed from the vaccines.[62] For diseases like malaria and 
tuberculosis, the current strategy is reduction in mortality and morbidity rather than prevention of 
infection altogether. However for viral infections including measles and con-genital rubella, the 
WHO views the outright removal of the pathogen as a feasible aim.[63] 
Conclusion 
Thus, in less than a hundred years, diagnostic virology has moved from a situation where the 
laboratory work was very specialised and difficult to undertake (and probably not really needed) to 
one where biomedical scientists who are virologists play a vital part in patient care and public health 
(as shown in the 2009 H1N1 influenza A pandemic and the 2014–2015 Ebola outbreak). There is now 
a better understanding of virus biology and the pathogenesis of viral infections, as well as the host 
immune response, than there was 50 years ago. The molecular genetics techniques available for 
diagnosis, strain differentiation of isolates and discovery of new viruses have the potential to 
contribute to the rapid development of anti-viral agents and vaccines. Point of care kits mean that it 
is possible to test yourself for viral infections such as HIV [64] in your own home, within minutes! 
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Table 1. Epidemiology of selected viral pathogens of humans in the United Kingdom. 
Virus Approximate annual 
incidence a 
Estimated 
prevalence b 
Mortality 
(average 
deaths per 
annum) 
Hepatitis B virus 1000 180000 500 
Measles virus 500-2000c N/Ae <1 
Human immunodeficiency 6000 100,000 500d 
Virus Respiratory syncytial 10-12,000c N/A 80 
Virus Norovirus 15,000 N/A 100-200 
Hepatitis C virus 18,000 214,000 400 
Genital herpes simplex virus 32,000 N/Rf N/A 
 
Data collated from several sources [55–58]. A Laboratory conﬁrmed new cases; b where recorded, 
for chronic infections; c annual incidence varies; d approximately 50% of deaths AIDS-related; e not  
applicable; f data not recorded. 
Figure 1.  Showing a particle*. Source: Figure provided by Mr I Phillips. *it is not possible to 
identify species from EM appearance. 
 
Figure 2. Electron micrograph of faecal sample showing norovirus particles. Source: Figure 
provided by Mr I Phillips. 
 
Figure 3. Fluorescence microscopy slide showing respiratory cells infected with RSV. Source: Figure 
provided by Mr I Phillips. 
 
 
Figure 4. Point of care device to test for norovirus antigen in faecal samples (negative result). 
Source: Figure provided by Dr S Pitt. 
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